Hospira`s Retacrit (darbepoetin alfa) Receives Suppl Approval in the U.S.
04 Jun 2024 //
FDA
Pfizer`s Hospira pulls 5 lots of hospital injectable drugs
23 May 2024 //
FIERCE PHARMA
Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine HCL
22 May 2024 //
FDA
Hospira`s Biologic Nivestym (filgrastim-aafi) Receives Approval in the U.S.
16 Feb 2024 //
FDA
Pfizer`s Hospira rings in new year with fresh round of recalls
27 Dec 2023 //
FIERCE PHARMA
Enforcement Report - Week of November 15, 2023
15 Nov 2023 //
FDA
Enforcement Report - Week of February 1, 2023
01 Feb 2023 //
FDA
Enforcement Report - Week of January 11, 2023
11 Jan 2023 //
FDA
Appeals court sides with Pfizer in patent fight with Astellas
05 Jan 2023 //
FIERCE PHARMA
Hospira`s Generic Regadenoson Receives Approval in the U.S.
31 Aug 2022 //
FDA
Hospira, Inc. Generic Bortezomib Receives Approval in the U.S.
26 Jul 2022 //
FDA
Hospira issues a recall for propofol due to visible particulate
16 Jul 2022 //
ENDPTS
Hospira`s Generic Pemetrexed Disodium Receives Approval in the U.S.
25 May 2022 //
FDA
Delaware court rules against Gilead and Astellas in years-long patent case
23 May 2022 //
ENDPTS
Eagle Reaches Settlement Agreement with Hospira Related to BENDEKA
19 Apr 2022 //
GLOBENEWSWIRE
Hospira`s Generic Bortezomib Receives Approval in the U.S.
10 Mar 2022 //
FDA
The Biosimilars Forum`s Julie Reed on What She`s Learned
19 Feb 2022 //
CENTERFORBIOSIMILARS
Hospira, Inc`s Generic Aztreonam Receives Approval In US
15 Nov 2021 //
FDA
Hospira, Inc’s Generics Aztreonam Receives Approvals In US
10 Nov 2021 //
FDA
BioCina completes takeover of Pfizer-owned Australia plant; and more
07 Oct 2021 //
ENDPTS
Enforcement Report - Week of September 22, 2021
22 Sep 2021 //
FDA
Recall report: Amino acid IV pulled after foreign substances found in batch
09 Sep 2021 //
ENDPTS
ICU Medical Issues a Voluntary Nationwide Recall of Aminosyn II 15%
03 Sep 2021 //
FDA
FDA Issues Form 483 to Hospira Inc
24 May 2021 //
FDA
FDA Issues Form 483 to Hospira
05 May 2021 //
FDA
FDA Issues Form 483 to Hospira Inc A Pfizer Company
21 Apr 2021 //
FDA
FDA Issues Form 483 to Hospira Inc. A Pfizer Company
21 Apr 2021 //
FDA
FDA Issues Form 483 to Hospira Inc.
21 Apr 2021 //
FDA
FDA Issues Form 483 to Hospira Boulder, Inc.
21 Apr 2021 //
FDA
Motion to Dismiss Denied in Amgen v. Hospira BPCIA
09 Apr 2021 //
BIGMOLECULEWATCH
Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
11 Mar 2021 //
KHN
Hospira`s Pemetrexed Receives Tentative Approval in US
11 Jan 2021 //
FDA
Par Pharmaceutical, Inc. v. Hospira, Inc. (Fed. Cir. 2020)
30 Nov 2020 //
PATENTDOCS
Hospira`s Generic Epoetin Alfa Receives Supplemental Approval in US
30 Jun 2020 //
FDA
Supreme Court Passes on Eli Lilly Patent Infringement Win
15 Jun 2020 //
BLOOMBERGLAW
Hospira`s Nyvepria (Pegfilgrastim) Receives Supplemental Approval in US
13 Jun 2020 //
FDA
Amgen Sues Pfizer and Hospira for Patent Infringement to Hospira’s Filgrastim
28 Apr 2020 //
BIGMOLECULEWATCH
Epogen IP Fight Ends With Hospira Paying More Than $70M
21 Apr 2020 //
LAW360
Pfizer Moves to Dismiss Amgen’s Suit Over Proposed Neulasta Biosimilar
18 Mar 2020 //
BIGMOLECULEWATCH
Hospira, Inc., et al.; Withdrawal of Approval of 15 Abbreviated NDA
21 Feb 2020 //
AMAZONAS
Amgen Sues Pfizer Over Proposed Neulasta Biosimilar
14 Feb 2020 //
BIGMOLECULEWATCH
Hospira Asks Federal Circuit to Take Fresh Look at Safe Harbor Ruling
22 Jan 2020 //
BIG MOLECULE WATCH
Amgen Inc. v. Hospira, Inc. (Fed. Cir. 2019)
19 Dec 2019 //
PATENTDOCS
Glenmark`s Baddi Mfg unit receives GMP certificate from European regulator
17 Dec 2019 //
ECONOMIC TIMES
Morton Grove`s Withdrawal of Approval of 21 Abbreviated New Drug Applications
02 Dec 2019 //
FEDERALREGISTER
Hospira`s Generic Bortezomib Receives Approval in US
09 Nov 2019 //
FDA
Pfizer scrambles to fill void after Teva stops making chemo drug
16 Oct 2019 //
FIERCE PHARMA
Catalent expands; Hospira and Novartis issue recalls
10 Sep 2019 //
FIERCE PHARMA
Eli Lilly & Co. v. Hospira, Inc. (Fed. Cir. 2019)
13 Aug 2019 //
PATENTDOCS